Source-grounded facts extracted from Structure Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Structure Therapeutics Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2026-06-17 meeting.
“Proposal 3: Advisory vote on the compensation of the Company’s named executive officers On an advisory basis, the shareholders approved the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual General Meeting.”
Structure Therapeutics Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-17 meeting.
“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s shareholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Structure Therapeutics Inc. shareholders approved Election of Directors at the 2026-06-17 meeting.
“Proposal 1: Election of Directors Ted W. Love M.D., Raymond Stevens, Ph.D. and Daniel G. Welch were elected as a Class III directors, to hold office until the 2029 Annual General Meeting of Shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal.”
Structure Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.
“Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.”
Structure Therapeutics Inc. amended Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. (effective 2026-05-07).
“On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), relating to the offer and sale of the Company’s American Depositary Shares (“ADSs”), each representing three ordinary shares, $0.0001 par value per ordinary share.”
Structure Therapeutics Inc. entered into GNE Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd valued at $100 million (effective 2025-12-30).
“On December 30, 2025, Gasherbrum Bio, Inc. ("Gasherbrum"), a wholly-owned subsidiary of Structure Therapeutics Inc. (the "Company"), entered into an agreement (the "GNE Agreement") with Genentech, Inc. ("Genentech") and F. Hoffmann-La Roche Ltd ("Roche" and together with Genentech, "GNE") that was the culmination of discussions initiated by Genentech’s inquiry regarding the availability of a license to certain patents of Gasherbrum”
Mark Bach departed as Chief Medical Officer at Structure Therapeutics Inc..
“On September 12, 2024, Mark Bach, M.D., Ph.D. entered into a separation and consulting agreement (the “Bach Separation and Consulting Agreement”) with Structure Therapeutics Inc. (the “Company”) in connection with his departure as Chief Medical Officer (“CMO”) as part of a planned succession, effective as of September 18, 2024 (the “Effective Date”).”
Angus Russell was appointed as Class I director at Structure Therapeutics Inc..
“appointed Angus Russell to the Board, effective August 26, 2024.”
Structure Therapeutics Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 totaled $26.0 million.
“Structure Therapeutics Inc. (the "Company") issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2024.”
Structure Therapeutics Inc. reported the year ended December 31, 2023 results: net income For the year ended December 31, 2023, net loss totaled $89.6 million.
“For the year ended December 31, 2023, net loss totaled $89.6 million, with non-cash stock-based compensation expense of $8.2 million”
Structure Therapeutics Inc. reported the fourth quarter of 2023 results: net income Net loss for the fourth quarter of 2023 totaled $24.5.
“Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million”
Structure Therapeutics Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 14, 2023, the Company issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023.”
Structure Therapeutics Inc. entered into Aconcagua-Schrödinger Agreement with Schrödinger, Inc. valued at up to an aggregate of $89.0 million (effective 2023-11-07).
“On November 7, 2023, Aconcagua Bio, Inc. (“Aconcagua”), a wholly-owned subsidiary of Structure Therapeutics Inc. (the “Company”), entered into a collaboration agreement (the “Aconcagua-Schrödinger Agreement”) with Schrödinger, Inc. (“Schrödinger”) to discover and develop novel, small molecule modulators of a specific target.”
Structure Therapeutics Inc. entered into Purchase Agreement with certain institutional investors valued at aggregate gross proceeds of approximately $300 million (effective 2023-09-29).
“On September 29, 2023, Structure Therapeutics Inc. (the “Company”) entered into a share purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”).”
Structure Therapeutics Inc. reported the second quarter ended June 30, 2023 results: net income Net loss totaled $23.3 million.
“Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2023.”
Ted Love, M.D. was appointed as Class III director and Chair of the Compensation Committee at Structure Therapeutics Inc..
“appointed Ted Love, M.D. to the Board, effective immediately.”
Structure Therapeutics Inc. entered into Sublease with Aligos Therapeutics, Inc. valued at approximately US$0.49 million (effective 2023-06-29).
“On June 29, 2023, Structure Therapeutics USA Inc., the Company’s wholly owned subsidiary (“Structure USA”) entered into a sublease agreement (the “Sublease”) with Aligos Therapeutics, Inc.”
Structure Therapeutics Inc. entered into Lab Lease with Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd. valued at approximately 1.99 million yuan, or approximately US$0.27 million (effective 2023-06-29).
“On June 29, 2023, Shanghai ShouTi, entered into a lease agreement (the “Lab Lease”) with Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd.”
Structure Therapeutics Inc. entered into Operations Lease with Shanghai Changtai Business Management Co., Ltd. valued at approximately 5.20 million yuan, or approximately US$0.72 million (effective 2023-06-29).
“On June 29, 2023, Shanghai ShouTi Biotechnology Co., Ltd., the Company’s wholly owned subsidiary. (“Shanghai ShouTi”) entered into a lease agreement (the “Operations Lease”) with Shanghai Changtai Business Management Co., Ltd.”
Structure Therapeutics Inc. engaged Ernst & Young LLP as its auditor.
“On May 30, 2023, the Audit Committee approved the engagement of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Structure Therapeutics Inc. dismissed PricewaterhouseCoopers LLP as its auditor.
“On May 30, 2023, the Audit Committee (the “Audit Committee”) of the Board of Directors of Structure Therapeutics Inc. (the “Company”) approved the dismissal of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm.”
Structure Therapeutics Inc. reported the first quarter ended March 31, 2023 results: net income $18.0 million.
“Net loss totaled $18.0 million for the first quarter of 2023”
Structure Therapeutics Inc.: Filed amended and restated memorandum and articles of association to authorize 500,000,000 ordinary shares, effective upon IPO closing (effective 2023-02-07).
“On February 3, 2023, and in connection with the consummation of Structure Therapeutics Inc.’s (the “Company”) initial public offering of its American Depositary Shares representing its ordinary shares (the “IPO”), the Company filed an amended and restated memorandum and articles of association (the “Restated Memorandum and Articles”), substantially in the form previously filed as Exhibit 3.2 to the Company’s Registration Statement on Form S-1 (File No. 333-269200) (as amended, the “Registration Statement”), with the Registrar of Companies of the Cayman Islands. The Restated Memorandum and Articles each became effective upon the closing of the Offering on February 7, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.